Generation of three induced pluripotent stem cell lines from patients with glycogen storage disease type III.


Journal

Stem cell research
ISSN: 1876-7753
Titre abrégé: Stem Cell Res
Pays: England
ID NLM: 101316957

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 03 04 2023
revised: 01 09 2023
accepted: 22 09 2023
medline: 6 11 2023
pubmed: 29 9 2023
entrez: 28 9 2023
Statut: ppublish

Résumé

Glycogen storage disease type III (GSDIII) is an autosomal recessive disorder characterized by a deficiency of glycogen debranching enzyme (GDE) leading to cytosolic glycogen accumulation and inducing liver and muscle pathology. Skin fibroblasts from three GSDIII patients were reprogrammed into induced pluripotent stem cells (iPSCs) using non-integrated Sendai virus. All of the three lines exhibited normal morphology, expression of pluripotent markers, stable karyotype, potential of trilineage differentiation and absence of GDE expression, making them valuable tools for modeling GSDIII disease in vitro, studying pathological mechanisms and investigating potential treatments.

Identifiants

pubmed: 37769385
pii: S1873-5061(23)00200-3
doi: 10.1016/j.scr.2023.103214
pii:
doi:

Substances chimiques

Glycogen Debranching Enzyme System 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103214

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lucille Rossiaud (L)

CECS, I-Stem, Corbeil-Essonne 91100, France; INSERM U861, I-Stem, Corbeil-Essonne 91100, France; UEVE U861, I-Stem, Corbeil-Essonne 91100, France; Genethon, 91000 Evry, France; Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare research Unit UMR_S951, 91000 Evry, France.

Emilie Pellier (E)

CECS, I-Stem, Corbeil-Essonne 91100, France; INSERM U861, I-Stem, Corbeil-Essonne 91100, France; UEVE U861, I-Stem, Corbeil-Essonne 91100, France.

Manon Benabides (M)

CECS, I-Stem, Corbeil-Essonne 91100, France; INSERM U861, I-Stem, Corbeil-Essonne 91100, France; UEVE U861, I-Stem, Corbeil-Essonne 91100, France.

Xavier Nissan (X)

CECS, I-Stem, Corbeil-Essonne 91100, France; INSERM U861, I-Stem, Corbeil-Essonne 91100, France; UEVE U861, I-Stem, Corbeil-Essonne 91100, France.

Giuseppe Ronzitti (G)

Genethon, 91000 Evry, France; Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare research Unit UMR_S951, 91000 Evry, France.

Lucile Hoch (L)

CECS, I-Stem, Corbeil-Essonne 91100, France; INSERM U861, I-Stem, Corbeil-Essonne 91100, France; UEVE U861, I-Stem, Corbeil-Essonne 91100, France. Electronic address: lhoch@istem.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH